Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy.

What Was Tested

The paper reports a study of NAD+, published as a randomized controlled trial.

Who Took Part

According to the abstract, 73 people were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The researchers used the Michigan Neuropathy Screening Instrument Questionnaire and Examination (MNSIQ and MNSIE), measured vibration perception threshold (VPT) with biothesiometer, and Cardiovascular Autonomic Reflex Tests (CARTs).

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

Blinding on both sides kept the people and researchers unaware of who received NAD+.

The comparison arm used a placebo, so changes seen with NAD+ could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger NAD+ study would be practical.

Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)].

Sudomotor function was assessed with SUDOSCAN, which measures electrochemical skin conductance in hands and feet (ESCH and ESCF).

Pain score (PS) was assessed with Pain DETECT questionnaire.

Quality of life was assessed by questionnaire.

What Was Measured

PubMed files the paper under topics including Diabetic Neuropathies, Vitamin B 12, Thioctic Acid, Pilot Projects, Vitamin B 6, Palmitic Acids and Ethanolamines.

The authors tagged it with the keywords diabetes mellitus type 2, diabetic neuropathy, neuropathic pain, pain, painful diabetic neuropathy and supplements.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of NAD+ in 73 people.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Nutrients), a journal based in Switzerland.

More context: the NAD+ compound page, all human trials.